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Summary. Amyotrophic lateral sclerosis (ALS) is a 
progressive neurodegenerative disease that primarily 
involves the motor neuron system. Of all patients with 
ALS, approximately 5%-10% of them are familial and 
most of the others are sporadic. Superoxide dismutase 1 
(SOD1) gene mutations are shown to be associated with 
about 20% of familial ALS (FALS) patients. FALS is 
neuropathologically classified into two subtypes: 
classical FALS in which degeneration is restricted to 
only motor neurons and FALS which is characterized by 
the degeneration of the posterior column in addition to 
the lesion of the motor neuron system. The neuronal 
Lewy body-like hyaline inclusion (LBHI) is  a 
characteristic neuropathological marker of mutant 
SOD1-linked FALS with posterior column involvement. 
Inclusions similar to the neuronal LBHIs have been 
discovered in astrocytes in certain patients with FALS 
exhibiting SODl gene mutations. The purpose of this 
review is to discuss the novel neuropathological 
significance of the astrocytic hyaline inclusions (Ast- 
HIS) and neuronal LBHIs in brain tissues from 
individuals with the posterior-column-involvement-type 
FALS with SODl gene mutations. In hematoxylin and 
eosin preparations, both Ast-HIS and neuronal LBHIs are 
eosinophilic inclusions and sometimes show eosino- 
philic cores with paler peripheral halos. Immunohisto- 
chemically, both inclusions are intensely positive for 
SODl .  At the ultrastructural level, both inclusions 
consist of approximately 15-25 nm-sized granule-coated 
fibrils and granular materials. Immunoelectron 
microscopically, these abnormal granule-coated fibrils 
and granular materials are positive for SOD1. Therefore, 
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the FALS disease process originating from SODl gene 
mutations occurs in astrocytes as well as neurons and is 
involved in the formation of both inclusions. 
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Introduction 
Amyotrophic lateral sclerosis (ALS) is a fatal and 
age-associated neurodegenerative disorder that primarily 
involves both upper and lower motor neurons (Hirano, 
1995, 1996). Despite this disease having been studied for 
over 120 years, its etiology is still unknown. Of all 
patients with ALS, approximately 5%-10% of them are 
familial and most of the others are sporadic (Hudson, 
1981; Juneja et al., 1997). The prevalence rate of ALS is 
approximately 5 to 10 cases per 100,000 population (de 
Belleroche et al., 1996). Neuropathologically, ALS is 
classified into three major types: 1) classical sporadic 
ALS (SALS), in which degeneration is restricted to only 
motor neurons; 2)  familial ALS (FALS); and 3) 
Guamanian ALS, in which there is the widespread 
development of Alzheimer's neurofibrillary tangles 
(NFTs). The SALS patients are predominantly male 
(ma1e:female = 2:1, Hudson, 1981) and the disease 
mostly begins in the fifth and sixth decade of life. This 
disease process is progressive, and most patients who are 
not placed on respirators die of respiratory muscle 
paralysis within 5 years of onset. The main clinical 
feature of the patients is progressive muscular atrophy 
generated from the loss of lower motor neurons and 
spasticity from the degeneration of upper motor neurons. 
The FALS patients demonstrate an autosomal-dominant 
















